The Scientist

» pharmaceuticals and developmental biology

Most Recent

image: Endo to Pay $8 Billion for Par

Endo to Pay $8 Billion for Par

By | May 19, 2015

The deal would create one of the five biggest generic drugmakers in the U.S.

0 Comments

image: Dino Snouts from Chicken Beaks

Dino Snouts from Chicken Beaks

By | May 13, 2015

Researchers tweak gene expression in chicken embryos that may have been crucial to the evolutionary transition from dinosaur noses to bird bills.

0 Comments

image: Drugmaker Teva Bids $40 Billion for Mylan

Drugmaker Teva Bids $40 Billion for Mylan

By | April 23, 2015

The Israel-based pharmaceutical company makes an unsolicited offer for a smaller, Netherlands-based rival as its main product faces competition from generics.

0 Comments

image: Viral Protector

Viral Protector

By | April 21, 2015

A retrovirus embedded in the human genome may help protect embryos from other viruses, and influence fetal development.

1 Comment

image: Contributors

Contributors

By | April 1, 2015

Meet some of the people featured in the April 2015 issue of The Scientist.

0 Comments

image: From Many, One

From Many, One

By | April 1, 2015

Diverse mammals, including humans, have been found to carry distinct genomes in their cells. What does such genetic chimerism mean for health and disease?

4 Comments

image: Short, Strong Signals

Short, Strong Signals

By | March 25, 2015

Methylation increases both the activity and instability of the signaling protein Notch.

0 Comments

image: AbbVie Wins Bidding War for Cancer Drugmaker

AbbVie Wins Bidding War for Cancer Drugmaker

By | March 5, 2015

The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.

0 Comments

image: Shire Makes $5.2 Billion Buy

Shire Makes $5.2 Billion Buy

By | January 13, 2015

The Irish drugmaker moves on from its terminated sale to AbbVie to purchase New Jersey-based NPS Pharmaceuticals.

0 Comments

image: Spinoff Company to Develop Rare Disease Drugs

Spinoff Company to Develop Rare Disease Drugs

By | January 7, 2015

Maryland-based Vtesse will work with the US National Institutes of Health to advance treatments for Niemann-Pick Type C disease and other lysosomal storage disorders.

1 Comment

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

  4. Another DNA Vaccine for Zika Shows Promise
RayBiotech